Category: Cancer

Publications and studies on developments in both cancer treatment and prevention.

Cyto-Immuno-Therapy for Cancer: A Pathway Elicited by Tumor-Targeted, Cytotoxic Drug-Packaged Bacterially Derived Nanocells – ScienceDirect

Cyto-Immuno-Therapy for Cancer: A Pathway Elicited by Tumor-Targeted, Cytotoxic Drug-Packaged Bacterially Derived Nanocells – ScienceDirect

EnGenIC is a local Sydney company that I had the great pleasure of working with for some time.

They are a group of Aussie scientists showing the world that Australia is still a centre of innovation, especially in medial technology.

They’ve been working hard for this amazing cancer treatment technology and have recently just been published again. This latest publication is linked below.

https://www.sciencedirect.com/science/article/pii/S1535610820300908

Geroncogenesis: Metabolic Changes during Aging as a Driver of Tumorigenesis: Cancer Cell

Geroncogenesis: Metabolic Changes during Aging as a Driver of Tumorigenesis: Cancer Cell

“Why does cancer risk increase as we age? Frequently attributed to the multi-hit hypothesis and the time required to accumulate genomic mutations, this question is a matter of ongoing debate. Here, we propose that the normal decline in oxidative metabolism during aging constitutes an early and important “hit” that drives tumorigenesis. Central to these metabolic changes are the sirtuins, a family of NAD+-dependent deacylases that have evolved as coordinators of physiological responses to nutrient intake and energetic demand. Thus, the modulation of sirtuins might be a fruitful approach to reversing the age-related metabolic changes that could underlie tumorigenesis.”

https://www.cell.com/cancer-cell/fulltext/S1535-6108(13)00534-5

Cordyceps militaris induces apoptosis in ovarian cancer cells through TNF-α/TNFR1-mediated inhibition of NF-κB phosphorylation | BMC Complementary Medicine and Therapies | Full Text

Cordyceps militaris induces apoptosis in ovarian cancer cells through TNF-α/TNFR1-mediated inhibition of NF-κB phosphorylation | BMC Complementary Medicine and Therapies | Full Text

“These results suggest that C. militaris inhibited ovarian cancer cell proliferation, survival, and migration, possibly through the coordination between TNF-α/TNFR1 signaling and NF-κB activation. Taken together, our findings provide a new insight into a novel treatment strategy for ovarian cancer using C. militaris.”

https://bmccomplementmedtherapies.biomedcentral.com/articles/10.1186/s12906-019-2780-5

KLF2 induces the senescence of pancreatic cancer cells by cooperating with FOXO4 to upregulate p21 – ScienceDirect

KLF2 induces the senescence of pancreatic cancer cells by cooperating with FOXO4 to upregulate p21 – ScienceDirect

“In this study, we showed that overexpression of KLF2 induced the senescence of pancreatic cancer cells and inhibited tumorigenesis, and knockdown of KLF2 inhibited senescence and p21 expression. In the molecular mechanism study, KLF2 was found to interact with FOXO4 and cooperated with FOXO4 to induce the expression of p21.”

https://www.sciencedirect.com/science/article/pii/S001448271930669X

Rapid Recognition and Targeted Isolation of Anti-HIV Daphnane Diterpenes from Daphne genkwa Guided by UPLC-MSn | Journal of Natural Products

Rapid Recognition and Targeted Isolation of Anti-HIV Daphnane Diterpenes from Daphne genkwa Guided by UPLC-MSn | Journal of Natural Products

“Daphnane diterpenes with a 5/7/6-tricyclic ring system exhibit potent anti-HIV activity but are found in low abundance as plant natural products. In this study, an effective approach based on mass spectrometric fragmentation pathways was conducted to specifically recognize and isolate anti-HIV compounds of this type from Daphne genkwa.”

https://pubs.acs.org/doi/10.1021/acs.jnatprod.9b00993

EnGeneIC Ltd Selected as Winner in Drug Delivery Technology category by Fierce Innovation Awards – LifeSciences Edition 2019

EnGeneIC Ltd Selected as Winner in Drug Delivery Technology category by Fierce Innovation Awards – LifeSciences Edition 2019

EnGeneIC Limited, a clinical-stage biopharmaceutical company advancing its proprietary EDV™ nanocell platform for targeted cyto-immunotherapy in cancer, announced that it is the winner in this year’s Drug Delivery Technology category given by Fierce Innovation Awards – LifeSciences Edition, which is a peer-reviewed awards program from the publisher of FierceBiotech and FiercePharma.

EnGeneIC’s EDV™ is a globally unique cyto-immunotherapy that is able to directly kill cancer cells as well as provoking a potent anti-tumor immune response with little to no toxicity, even in late stage drug-resistant cancers.

https://www.prnewswire.com/news-releases/engeneic-ltd-selected-as-winner-in-drug-delivery-technology-category-by-fierce-innovation-awards–lifesciences-edition-2019-300977187.html

From Tea to treatment; Epigallocatechin Gallate and its potential involvement in minimizing the metabolic changes in Cancer

From Tea to treatment; Epigallocatechin Gallate and its potential involvement in minimizing the metabolic changes in Cancer

As the most abundant bioactive polyphenol in green tea, epigallocatechin gallate (EGCG) is a promising natural product that should be utilized in the discovery and development of potential drug leads. Due to its association with chemoprevention, EGCG may find a role in the development of therapeutics for prostate cancer. Natural products have long been employed as a scaffold for drug design, as their already noted bioactivity can help accelerate the development of novel treatments. Green tea and the EGCG contained within have become associated with chemoprevention, and both in vitro and in vivo studies have correlated EGCG to inhibiting cell growth and increasing the metabolic stress of cancer cells, possibly giving merit to its long utilized therapeutic use in traditional therapies. There is accumulating evidence to suggest that EGCG’s role as an inhibitor of the PI3K/Akt/mTOR signaling cascade, acting upon major axis points within cancer survival pathways. The purpose of this review is to examine the research conducted on tea along with EGCG in the areas of the treatment of and/or prevention of cancer. This review discusses Camellia sinensis, as well as the bioactive phytochemical compounds contained within. Clinical uses of tea are explored, and possible pathways for activity are discussed before examining the evidence for EGCG’s potential for acting on these processes. EGCG is identified as being a possible lead phytochemical for future drug design investigations.

https://www.sciencedirect.com/science/article/pii/S0271531719305007?dgcid=rss_sd_all&utm_source=researcher_app&utm_medium=referral&utm_campaign=RESR_MRKT_Researcher_inbound

Save Aussie Supplements – call to action

Save Aussie Supplements – call to action

Opinion – While unsafe products should be regulated, an individual should be free to research and trial compounds that may or may not yet have shown clear evidence or clinical trials for efficacy.

Medial technology and knowledge is constantly changing and we cannot be held ransom to a slow moving TGA locking up beneficial compounds simply because they’ve not yet tested or studied them.

Click the link below if you agree to show the TGA that we need and want access to supplements that can improve our health.

https://www.saveaussiesupplements.com.au/

Creatine powers T cells’ fight against cancer — ScienceDaily

Creatine powers T cells’ fight against cancer — ScienceDaily

Creatine, the organic acid that is popularly taken as a supplement by athletes and bodybuilders, serves as a molecular battery for immune cells by storing and distributing energy to power their fight against cancer, according to new UCLA research.

Creatine powers T cells’ fight against cancer — ScienceDaily
Researchers discover a new way that telomerase acts to keep cancer cells multiplying

Researchers discover a new way that telomerase acts to keep cancer cells multiplying

Researchers were surprised to discover a new way that an enzyme in cancer cells, telomerase, acts to keep cancer cells multiplying. This could mean a faster way to stop cancer cells in their tracks. Tracy Bryan, the lead author on research released in Science Advances, was initially skeptical of the findings.

Researchers discover a new way that telomerase acts to keep cancer cells multiplying
Association among the prognostic nutritional index, completion of adjuvant chemotherapy, and cancer-specific survival after curative resection of stage II/III gastric cancer | European Journal of Clinical Nutrition

Association among the prognostic nutritional index, completion of adjuvant chemotherapy, and cancer-specific survival after curative resection of stage II/III gastric cancer | European Journal of Clinical Nutrition

https://www.nature.com/articles/s41430-019-0502-1